C07K 16/283
Against fc-receptors
Official title: {against Fc-receptors, e.g. CD16, CD32, CD64 (CD23 C07K16/2851)}
C07K16/283 (Against fc-receptors) appears on 660 US grants and 1,364 published applications in this corpus.
Search patents in C07K- Granted patents
- 660
- Published applications
- 1,364
- Assignees
- 445
- Inventors
- 2,037
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1988 | 1 | 0 |
| 1989 | 0 | 0 |
| 1990 | 3 | 0 |
| 1991 | 0 | 0 |
| 1992 | 1 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 4 | 0 |
| 1998 | 9 | 0 |
| 1999 | 6 | 0 |
| 2000 | 6 | 0 |
| 2001 | 11 | 8 |
| 2002 | 8 | 6 |
| 2003 | 1 | 12 |
| 2004 | 2 | 13 |
| 2005 | 0 | 21 |
| 2006 | 5 | 20 |
| 2007 | 1 | 23 |
| 2008 | 10 | 27 |
| 2009 | 6 | 32 |
| 2010 | 10 | 42 |
| 2011 | 18 | 22 |
| 2012 | 25 | 30 |
| 2013 | 18 | 40 |
| 2014 | 25 | 34 |
| 2015 | 24 | 42 |
| 2016 | 33 | 70 |
| 2017 | 21 | 56 |
| 2018 | 31 | 51 |
| 2019 | 45 | 83 |
| 2020 | 35 | 90 |
| 2021 | 52 | 104 |
| 2022 | 53 | 96 |
| 2023 | 47 | 112 |
| 2024 | 56 | 123 |
| 2025 | 62 | 121 |
| 2026 | 31 | 86 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Fc-binding protein having improved acid stability, production method for said protein, and antibody-adsorbing agent using said protein6 Oct 2026US 12,753,235 B2Tosoh Corporation
- Use of FcgammaRIII inhibitor in preparation of medicament for treating pulmonary fibrosis15 Sep 2026US 12,735,489 B2Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences
- Humanized anti-human CD89 antibodies and uses thereof15 Sep 2026US 12,735,490 B2JJP Biologics SP. Z O.O.
- Anti-FcRn antibodies and methods for treating myasthenia gravis1 Sep 2026US 12,723,087 B2Momenta Pharmaceuticals, Inc.
- Molecules that bind to CD66e polypeptides11 Aug 2026US 12,703,760 B2University of Pittsburgh—Of the Commonwealth System of Higher Education
- Anti-vegf protein compositions and methods for producing the same8 Oct 2026US 2026/0308231 A1Regeneron Pharmaceuticals, Inc.
- Anti-vegf protein compositions and methods for producing the same8 Oct 2026US 2026/0308232 A1Regeneron Pharmaceuticals, Inc.
- Anti-vegf protein compositions and methods for producing the same8 Oct 2026US 2026/0308233 A1Regeneron Pharmaceuticals, Inc.
- A high-concentration monoclonal antibody formulation and uses thereof8 Oct 2026US 2026/0308245 A1Jiangsu Biojetay Biotechnology Co., Ltd.
- Cd3 binding molecules8 Oct 2026US 2026/0308254 A1Merus N.V.
Most cited
By later US patents
- Optimized Fc variants463US 7,317,091 B2Xencor, Inc. · 2008
- Molecules with extended half-lives, compositions and uses thereof342US 7,083,784 B2MedImmune, LLC · 2006
- Frozen piercing implements and methods for piercing a substrate284US 8,784,385 B2The Invention Science Fund I, LLC · 2014
- Therapeutic compounds comprised of anti-Fc receptor antibodies262US 5,837,243 AMedarex, Inc. · 1998
- Identification and engineering of antibodies with variant Fc regions and methods of using same227US 7,355,008 B2MacroGenics, Inc. · 2008